PGNY
Company Description
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.29B | 1.17B | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Net Income | 58.52M | 54.34M | 62.04M | 30.36M | 65.77M | 46.46M | (8.57M) | 661,000 | (12.45M) |
| EPS | 0.68 | 0.59 | 0.65 | 0.33 | 0.74 | 0.54 | -0.10 | 0.01 | -2.19 |
| Free Cash Flow | 191.78M | 173.70M | 185.17M | 77.15M | 23.91M | 35.17M | (4.49M) | 1.69M | (10.09M) |
| FCF / Share | 2.25 | 1.90 | 1.95 | 0.84 | 0.27 | 0.41 | -0.05 | 0.02 | -1.77 |
| Operating CF | 210.19M | 179.10M | 188.81M | 80.39M | 26.04M | 36.20M | (1.53M) | 2.27M | (9.47M) |
| Total Assets | 742.43M | 607.10M | 756.62M | 542.99M | 358.06M | 253.93M | 150.43M | 41.32M | 34.96M |
| Total Debt | 24.00M | 19.27M | 19.39M | 7.71M | 8.65M | 9.55M | 0 | 253,000 | 5.19M |
| Cash & Equiv | 112.24M | 162.31M | 97.30M | 120.08M | 91.41M | 70.31M | 80.38M | 127,000 | 4.69M |
| Book Value | 516.04M | 422.06M | 553.43M | 376.97M | 251.82M | 166.95M | 114.27M | 11.12M | 10.69M |
| Return on Equity | 0.11 | 0.13 | 0.11 | 0.08 | 0.26 | 0.28 | -0.07 | 0.06 | -1.16 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 328.50M | 318.40M | 313.35M | 332.87M | 324.04M | 298.43M | 286.62M | 304.09M | 278.08M | 269.94M | 280.89M | 279.37M |
| Net Income | 24.23M | 12.48M | 13.86M | 17.11M | 15.06M | 10.53M | 10.42M | 16.48M | 16.90M | 13.47M | 15.90M | 14.99M |
| EPS | 0.30 | 0.15 | 0.16 | 0.20 | 0.18 | 0.12 | 0.12 | 0.18 | 0.18 | 0.14 | 0.17 | 0.16 |
| Free Cash Flow | 39.60M | 48.59M | 42.90M | 50.24M | 46.97M | 50.27M | 42.72M | 55.83M | 24.88M | 36.98M | 53.23M | 75.25M |
| FCF / Share | 0.49 | 0.57 | 0.50 | 0.59 | 0.55 | 0.55 | 0.47 | 0.59 | 0.26 | 0.39 | 0.56 | 0.79 |
| Operating CF | 45.95M | 54.20M | 47.58M | 55.51M | 49.81M | 52.16M | 44.52M | 56.69M | 25.73M | 37.66M | 54.18M | 76.01M |
| Total Assets | 698.34M | 742.43M | 795.23M | 760.95M | 730.28M | 607.10M | 659.97M | 698.63M | 794.30M | 756.62M | 726.51M | 681.54M |
| Total Debt | 27.28M | 27.73M | 24.73M | 25.50M | 26.00M | 19.27M | 16.62M | 19.87M | 19.29M | 19.39M | 17.70M | 18.14M |
| Cash & Equiv | 132.65M | 112.24M | 133.98M | 132.51M | 109.24M | 162.31M | 91.48M | 94.96M | 114.96M | 97.30M | 158.07M | 170.57M |
| Book Value | 439.34M | 516.04M | 560.00M | 515.02M | 467.16M | 422.06M | 434.88M | 456.19M | 571.60M | 553.43M | 515.39M | 469.50M |
| Return on Equity | 0.06 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 | 0.03 | 0.02 | 0.03 | 0.03 |
